AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30793493 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current cardioversion (DCCV)
Number of subjects: 67
Study 30793493 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker (PPM) + atrioventricular node ablation (AVNA) + DCCV
Number of subjects: 67
Study 30793493 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 67
Study 30793493 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study 26581545 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent change implementation approach
Number of subjects: 0
Study 26581545 — intervention group
Group type: COMPARATOR
Intervention: Planned change implementation approach
Number of subjects: 0
Study 26431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallikrein injection (0.15 PNA unit) plus 100 mL saline, intravenous infusion, once a day for 14 days
Number of subjects: 110
Study 26431650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 110
Study 26431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallikrein injection for L subtype patients
Number of subjects: 110
Study 26431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallikrein injection for S subtype patients
Number of subjects: 110
Study 26431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein treatment group
Number of subjects: 110
Study 26431650 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 23806459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 μg once daily
Number of subjects: 548
Study 23806459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 17049710 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological threat stimuli (CS+) directed towards participants
Number of subjects: 0
Study 17049710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural threat stimuli (CS+) directed towards participants
Number of subjects: 0
Study 17049710 — intervention group
Group type: COMPARATOR
Intervention: Biological threat stimuli (CS-) not directed towards participants
Number of subjects: 0
Study 17049710 — intervention group
Group type: COMPARATOR
Intervention: Cultural threat stimuli (CS-) not directed towards participants
Number of subjects: 0
Study 16279294 — intervention group
Group type: EXPERIMENTAL
Intervention: VDIS decision support system
Number of subjects: 7348
Study 16279294 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7348
Study 11010937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (n = 10)
Number of subjects: 21
Study 11010937 — intervention group
Group type: COMPARATOR
Intervention: No sucrose (Control group, n = 11)
Number of subjects: 21
Study 8971306 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d.
Number of subjects: 150
Study 8971306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d.
Number of subjects: 150
Study 8971306 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d.
Number of subjects: 150
Study 1572756 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 12
Study 1572756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4064576 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 6
Study 4064576 — intervention group
Group type: COMPARATOR
Intervention: Cold-pressor test (control)
Number of subjects: 6
Study 31144591 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial gland ablation (PGA)
Number of subjects: 0
Study 31144591 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective performance criteria/goals (OPC/OPG)
Number of subjects: 0
Study 26340920 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group (0.7 g/kg)
Number of subjects: 87
Study 26340920 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol group
Number of subjects: 87
Study 25766455 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet combined with 12 weeks of abdominal resistance training
Number of subjects: 40
Study 25766455 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 40
Study 22835498 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification by heart rate (HR)
Number of subjects: 36504
Study 22835498 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification by systolic blood pressure (SBP)
Number of subjects: 36504
Study 22835498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with GCS=15
Number of subjects: 36504
Study 22835498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with GCS<12
Number of subjects: 36504
Study 20935607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermuscular minimally invasive surgery (MIS)
Number of subjects: 30
Study 20935607 — intervention group
Group type: COMPARATOR
Intervention: Standard lateral transmuscular approach
Number of subjects: 30
Study 19330801 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated gum (40 mg)
Number of subjects: 118
Study 19330801 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 118
Study 19330801 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 118
Study 17028353 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol 50 micrograms every 4 hours for up to five doses
Number of subjects: 50
Study 17028353 — intervention group
Group type: COMPARATOR
Intervention: oxytocin infusion after artificial rupture of membranes
Number of subjects: 50
Study 17028353 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol
Number of subjects: 50
Study 14970777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 42
Study 14970777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 42
Study 14970777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine and Bethanechol
Number of subjects: 42
Study 10905597 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 156
Study 10905597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 9166301 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous closure with looped polyglyconate suture
Number of subjects: 614
Study 9166301 — intervention group
Group type: COMPARATOR
Intervention: Interrupted closure with interrupted polyglycolic acid
Number of subjects: 614
Study 8268429 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 45
Study 8268429 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural analgesia
Number of subjects: 45
Study 3754633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic stimulation (body stroking and passive movements of the limbs for three, 15-minute periods per day for 10 days)
Number of subjects: 20
Study 3754633 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 control neonates)
Number of subjects: 20
Study 3754633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic stimulation
Number of subjects: 20
Study 31915511 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Vitamin B complex
Number of subjects: 30
Study 31915511 — intervention group
Group type: COMPARATOR
Intervention: Synthetic Vitamin B complex
Number of subjects: 30
Study 28977340 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1528
Study 28977340 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported PA
Number of subjects: 1528
Study 28977340 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer CPMs
Number of subjects: 1528
Study 28977340 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 1528
Study 27028269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg extended release, 8 doses)
Number of subjects: 20
Study 27028269 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg extended release, 8 doses)
Number of subjects: 20
Study 27028269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25156683 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 450
Study 25156683 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 450
Study 22292424 — intervention group
Group type: EXPERIMENTAL
Intervention: BetaSweet carrot juice
Number of subjects: 69
Study 22292424 — intervention group
Group type: EXPERIMENTAL
Intervention: Balero carrot juice
Number of subjects: 69
Study 22292424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (carrot juice intake)
Number of subjects: 69
Study 20724487 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothie containing 22.5 g blueberry bioactives
Number of subjects: 32
Study 20724487 — intervention group
Group type: COMPARATOR
Intervention: Smoothie of equal nutritional value without added blueberry bioactives (placebo group)
Number of subjects: 32
Study 18946063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary‐vein isolation
Number of subjects: 81
Study 18946063 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular‐node ablation with biventricular pacing
Number of subjects: 81
Study 16088807 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (3 concentrations: 10(4.7), 10(5.2), 10(6.1) focus-forming units)
Number of subjects: 2464
Study 16088807 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 2464
Study 16088807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study 12834518 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention including a 3-hour continuing medical education course, training in management of UI, patient educational materials, and on-site physician and office support.
Number of subjects: 1145
Study 12834518 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1145
Study 10502364 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestible fat
Number of subjects: 18
Study 10502364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester
Number of subjects: 18
Study 10502364 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 8698630 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine and cisplatin (VP)
Number of subjects: 134
Study 8698630 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin C, vindesine and cisplatin (MVP)
Number of subjects: 134
Study 8698630 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 134
Study 1928272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3% ophthalmic solution
Number of subjects: 148
Study 1928272 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (fortified cefazolin 33 mg/ml and fortified gentamicin or tobramycin 14 mg/ml)
Number of subjects: 148
Study 7153945 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectancy group (n = 8)
Number of subjects: 32
Study 7153945 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectancy group (n = 8)
Number of subjects: 32
Study 31699709 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein with poly-ICLC
Number of subjects: 0
Study 31699709 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein with poly-ICLC and montanide
Number of subjects: 0
Study 31699709 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30982711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 6
Study 30982711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with Vatinoxan
Number of subjects: 6
Study 30982711 — intervention group
Group type: COMPARATOR
Intervention: Vatinoxan alone
Number of subjects: 6
Study 29037631 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowen Therapy
Number of subjects: 34
Study 29037631 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 34
Study 26502357 — intervention group
Group type: COMPARATOR
Intervention: TAK-385 (0 [placebo], 80, 120, 180, or 360 mg) single doses
Number of subjects: 176
Study 26502357 — intervention group
Group type: COMPARATOR
Intervention: TAK-385 (0, 20, 40, 80, or 180 mg) daily for 14 days
Number of subjects: 176
Study 26502357 — intervention group
Group type: COMPARATOR
Intervention: TAK-385 (40 [with loading dose], 60, 80, or 160 mg) daily for 28 days
Number of subjects: 176
Study 26502357 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of TAK‐385 on day 28
Number of subjects: 176
Study 26502357 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-385 (40-180 mg/d)
Number of subjects: 176
Study 24912901 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Skills Training (CST) program (2-day workshop)
Number of subjects: 30
Study 24912901 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 22383508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ascorbic acid (Asc) 2-g single dose
Number of subjects: 0
Study 22383508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19201328 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) - Transbond Plus, 3M Unitek, Monrovia, Calif
Number of subjects: 25
Study 19201328 — intervention group
Group type: COMPARATOR
Intervention: Conventional etch and sealant (CES) - Light Bond, Reliance Orthodontic Products, Itasca, Ill
Number of subjects: 25
Study 19201328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SEP and CES)
Number of subjects: 25
Study 17543874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 1077
Study 17543874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1077
Study 15390067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 21
Study 15390067 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study 11453971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg daily for 12 weeks
Number of subjects: 58
Study 11453971 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 58
Study 8158539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg monthly)
Number of subjects: 214
Study 8158539 — intervention group
Group type: COMPARATOR
Intervention: Low-dose daily TMP-SMX (400-80 mg)
Number of subjects: 214
Study 8158539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 214
Study 8158539 — intervention group
Group type: COMPARATOR
Intervention: Low-dose daily TMP-SMX
Number of subjects: 214
Study 3414587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (46% of calories)
Number of subjects: 6
Study 3414587 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (25% of calories)
Number of subjects: 6
Study 31132542 — intervention group
Group type: EXPERIMENTAL
Intervention: First episode psychosis (FEP) smokers
Number of subjects: 613
Study 31132542 — intervention group
Group type: EXPERIMENTAL
Intervention: Established psychosis smokers
Number of subjects: 613
Study 31132542 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly nicotine dependent smokers in established psychosis
Number of subjects: 613
Study 27832717 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 898
Study 27832717 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 898
Study 25442784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity falls prevention education program
Number of subjects: 1206
Study 25442784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1206
Study 23835543 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of plastic wrap (NeoWrap) immediately after birth; infants encased from neck down without being dried, head dried with a prewarmed towel, and a hat added.
Number of subjects: 92
Study 23835543 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group); infants transferred to prewarmed radiant warmer, dried, and warm towels and a hat applied.
Number of subjects: 92
Study 21540865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (500, 1000 and 2000 mg) twice weekly with standard doses of cetuximab, cisplatin and 5-fluorouracil
Number of subjects: 10
Study 18465410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 9
Study 18465410 — intervention group
Group type: COMPARATOR
Intervention: Hearing Aids (HAs)
Number of subjects: 9
Study 18465410 — intervention group
Group type: COMPARATOR
Intervention: Longer-term CI users
Number of subjects: 9
Study 18465410 — intervention group
Group type: COMPARATOR
Intervention: HA-only users
Number of subjects: 9
Study 16971235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (10 mg initially, reduced daily to 2 mg over 5 days)
Number of subjects: 0
Study 16971235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar 5-day gradual reduction regimen)
Number of subjects: 0
Study 14634172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sondhi Rapid Set (SD) adhesive
Number of subjects: 40
Study 14634172 — intervention group
Group type: COMPARATOR
Intervention: Maximum Cure (MC) adhesive
Number of subjects: 40
Study 14634172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sondhi Rapid Set (SD) adhesive (maxillary arch)
Number of subjects: 40
Study 14634172 — intervention group
Group type: COMPARATOR
Intervention: Maximum Cure (MC) adhesive (maxillary arch)
Number of subjects: 40
Study 14634172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sondhi Rapid Set (SD) adhesive (mandibular arch)
Number of subjects: 40
Study 14634172 — intervention group
Group type: COMPARATOR
Intervention: Maximum Cure (MC) adhesive (mandibular arch)
Number of subjects: 40
Study 10663358 — intervention group
Group type: COMPARATOR
Intervention: HRT (piperazine estrone sulfate 0.625‐0.937 mg daily +/‐ medroxyprogesterone acetate 2.5 mg daily)
Number of subjects: 71
Study 10663358 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus calcitriol (0.25 microg twice daily)
Number of subjects: 71
Study 10663358 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 71
Study 10663358 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus calcitriol
Number of subjects: 71
Study 8640974 — intervention group
Group type: EXPERIMENTAL
Intervention: [13N]ammonia
Number of subjects: 30
Study 8640974 — intervention group
Group type: COMPARATOR
Intervention: [15O]water
Number of subjects: 30
Study 1889777 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with PEX
Number of subjects: 164
Study 1889777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 6498792 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (96 micrograms/day)
Number of subjects: 44
Study 6498792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/day)
Number of subjects: 44
Study 6498792 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E combination
Number of subjects: 44
Study 6498792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3514154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate 12 percent lotion
Number of subjects: 0
Study 3514154 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-based creme (creme B)
Number of subjects: 0
Study 29076786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-induced cardiac arrest (AiCA)
Number of subjects: 130
Study 29076786 — intervention group
Group type: COMPARATOR
Intervention: Temporary clipping (TC)
Number of subjects: 130
Study 26492924 — intervention group
Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (HDF)
Number of subjects: 2793
Study 26492924 — intervention group
Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (HDF) with high delivered convection volume (>23 L per 1.73 m² BSA per session)
Number of subjects: 2793
Study 23181455 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH 2 wellness plus
Number of subjects: 23
Study 23181455 — intervention group
Group type: COMPARATOR
Intervention: DASH 2 wellness only standard of care
Number of subjects: 23
Study 22454089 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 2054
Study 22454089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2054
Study 20942279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding treatment
Number of subjects: 60
Study 20942279 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment (Tiopronin and Xuezhikang capsule)
Number of subjects: 60
Study 18090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (estradiol: 0.72 mg/2 d)
Number of subjects: 30
Study 18090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (conjugated equine estrogens: 0.625 mg/d)
Number of subjects: 30
Study 16829649 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12653409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapsers
Number of subjects: 893
Study 12653409 — intervention group
Group type: COMPARATOR
Intervention: Abstainers
Number of subjects: 893
Study 10389805 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4.5 microg/kg)
Number of subjects: 104
Study 10389805 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 104
Study 8889115 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g creatine daily
Number of subjects: 10
Study 8889115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis using GIA and TA staplers after right hemicolectomy
Number of subjects: 0
Study 2064291 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomoses after right hemicolectomy
Number of subjects: 0